自身免疫性溶血性贫血 中国就医指南

Autoimmune Hemolytic Anemia (AIHA) is a rare, heterogeneous hematologic disorder characterized by the immune-mediated destruction of autologous red blood cells (RBCs), leading to hemolysis and consequent anemia. It arises when the body’s immune system mistakenly produces autoantibodies—most commonly IgG (warm AIHA) or IgM (cold agglutinin disease)—that bind to RBC surface antigens, triggering complement activation and/or macrophage-mediated phagocytosis in the spleen or liver. Less common subtypes include mixed-type and drug-induced AIHA. Pathogenesis involves loss of B-cell tolerance, dysregulated T-follicular helper cell activity, impaired regulatory T-cell function, and genetic predispositions (e.g., polymorphisms in FCGR genes or HLA-DRB1*03/04). Secondary AIHA may accompany lymphoproliferative disorders (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma), systemic autoimmune diseases (e.g., SLE, rheumatoid arthritis), infections (e.g., Mycoplasma pneumoniae, EBV, HIV), or immunomodulatory therapies. Epidemiologically, AIHA affects approximately 1–3 per 100,000 individuals annually, with bimodal peaks in childhood (often post-infectious) and older adulthood (median age 50–70 years). Females are affected slightly more often than males (F:M ≈ 1.3:1). Risk factors include underlying autoimmune or hematologic malignancies, prior splenectomy, certain medications (e.g., fludarabine, alpha-methyldopa), and genetic susceptibility. Untreated or refractory AIHA can cause profound fatigue, dyspnea, pallor, jaundice, dark urine, tachycardia, and—in severe cases—high-output heart failure, renal injury from hemoglobinuria, or thromboembolic complications due to chronic inflammation and hypercoagulability. Quality of life is significantly impaired: patients report persistent fatigue, reduced physical stamina, anxiety about hemolytic crises, treatment-related side effects (e.g., steroid-induced insomnia, weight gain, osteoporosis), and social withdrawal due to unpredictable symptom flares. Long-term management requires vigilant monitoring for relapse, secondary malignancy, and iatrogenic complications—especially in elderly patients on prolonged immunosuppression. Psychosocial support, patient education on infection prevention, and individualized treatment escalation strategies are integral to holistic care.

# 自身免疫性溶血性贫血（AIHA）治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

• •一线药物治疗（温抗体型初治患者）：泼尼松0.5–1.5 mg/kg/d，起始疗程4–6周；费用：药费80–300元/月 + 血常规+网织红细胞+Coombs试验+LDH+胆红素等检验费600–900元/次
• •二线治疗（糖皮质激素无效或依赖）：利妥昔单抗375 mg/m²×4周（国产/进口），费用：12,000–28,000元/疗程；含输注监护及感染筛查（EBV/乙肝/HIV等）1,200–1,800元
• •支持治疗：静脉丙种球蛋白（IVIG）2 g/kg单疗程，费用：8,000–15,000元；红细胞输注（辐照去白）2U/次，费用：1,600–2,400元（含交叉配血及溶血风险评估）

二、手术/核心介入方案

• •脾切除术（难治性温抗体型、IgG主导、无禁忌证者）：腹腔镜微创术，术前需完成Tc-99m标记红细胞扫描及疫苗接种；术前检查（心肺功能+凝血+免疫评估）2,500–3,800元；手术+住院（7–10天）总费用：32,000–45,000元

三、特殊复杂方案

• •冷抗体型AIHA（CAD）耐药者：硼替佐米联合利妥昔单抗，费用：25,000–42,000元/周期；伴严重血栓/肾衰者需血浆置换（单次3,200–4,500元，通常3–5次）

四、方案快速选择指南

• •预算有限初治者：首选泼尼松+规范随访（首月总支出≤2,500元）
• •中高预算难治者：利妥昔单抗±小剂量激素（单疗程预算≤35,000元）
• •反复溶血危象/脾亢者：腹腔镜脾切除（总预算≤50,000元，长期获益明确）